Trinity College Dublin
|As first author||104|
|As last author||165|
Anne F McGettrick(19)
Sinead C Corr(16)
Sarah L Doyle(16)
Eva M. Palsson-McDermott(14)
Rebecca C Coll(11)
Claire E McCoy(9)
Matthew A Cooper(9)
Susan R Quinn(8)
Seth L Masters(8)
Paul N. Moynagh(8)
Avril A B Robertson(8)
... and 149 others
These arethe12 unique sources for Luke Anthony John O'Neill's 261 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Dublin City University||2|
|Ireland -> Dublin City University -> PubMed||2|
|Ireland -> Maynooth University||10|
|Ireland -> Maynooth University -> PubMed||2|
|Ireland -> Royal College of Surgeons in Ireland||5|
|Ireland -> Royal College of Surgeons in Ireland -> PubMed||5|
|Ireland -> Teagasc||2|
|Ireland -> Teagasc -> PubMed||2|
|Ireland -> Trinity College Dublin||242|
|Ireland -> Trinity College Dublin -> PubMed||127|
|Ireland -> University College Dublin||2|
|Ireland -> University College Dublin -> PubMed||1|
The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression of Toll-like Receptor 14 interaction with CD14 during Toll-like Receptor mediated signalling. The invention further provides screening assays to identify compounds which have utility in preventing the association of Toll-like Receptor 14 and CD14.
An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLRl 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes.
An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus i s not expressed or is expressed but is non-functional. Also described is the u se of a vaccinia virus A46R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/o r inhibition of IL1R/TLR superfamily signalling.
An orthopoxvirus vector, such as vaccinia, is described in which the A52R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A52R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signalling.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.